Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549

Wu, Dongming; Zhang, Peng; Xu, Guangchao; Tong, Aiping; Zhou, Cong; Lang, Jinyi; Wang, Chunting

doi:10.7314/apjcp.2015.16.4.1507

Cited by 7 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings indicate that p53 also plays an important role in the apoptotic pathway triggered by KMU-193 in A549 cells. Increasing evidence suggests a close link between induction of apoptosis in lung cancer cells and expression and/or activity of apoptosis-regulated protein, including p-Akt (Kim et al, 2013;Wu et al, 2015). Besides, it has been reported that p53 can activate the PTEN promoter leading to increased expression levels of PTEN, a negative regulator of the PI3K/Akt pathway (Feng, 2010).…”

Section: Discussionmentioning

confidence: 99%

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

Choi

Shin²,

Lee³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

Choi

Shin²,

Lee³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Apoptotic cells were quantified using the Annexin V/propidium iodide (PI) double staining method and analysis of phosphatidylserine on the outer surface of apoptotic cell membranes ( 29 ). The treated 4T1 cells received 10-Gy irradiation, were harvested after 72 h, and washed twice with PBS.…”

Section: Methodsmentioning

confidence: 99%

Novel recombinant protein FlaA N/C increases tumor radiosensitivity via NF-κB signaling in murine breast cancer cells

Fan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

The recombinant protein flagellin A (FlaA) N/C, derived from the flagellin protein of Legionella pneumophila, has been shown to increase the expression of cytoprotective cytokines, activate the nuclear factor-κB (NF-κB) signaling pathway, and increase the survival of mice following total body irradiation. Determi ning whether FlaA N/C has a sensitizing effect on tumor radiation or a direct tumoricidal effect is critical for its application as an effective radiation protection agent. The present study investigated the molecular mechanism underlying the tumor radiosensitivity of FlaA N/C. FlaA N/C was found to increase tumor apoptosis and autophagy, regulate the cell cycle and increase radiosensitivity in 4T1 tumor cells. Furthermore, FlaA N/C was found to promote radiosensitivity by activating NF-κB signaling. Finally, the present study analyzed FlaA N/C-enhanced radiosensitivity in animal models, and FlaA N/C was found to significantly prolong the survival period of mice after total body radiation. This indicates that FlaA N/C might be a novel radiation sensitizer in tumor radiation therapy.

show abstract

“…Therefore, establishing a treatment model to mimic the first-line second-line treatment is important, as it can be used to confirm the known clinical trial information, to analyze the mechanism and to test other drugs in the future. The inhibitory effects of docetaxel and pemetrexed on cell proliferation have been demonstrated (18,19). The present study compared the inhibitory effect of the docetaxel-pemetrexed (Doc-Pem) group with that of the pemetrexed-docetaxel (Pem-Doc) group.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma

Wang

Guan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Lung cancer is one of the most prevalent types of cancer in the world. Surgery, chemotherapy and radiotherapy are used clinically as treatments for numerous cancers. Due to the appearance of drug resistance, the remission rate is limited to 40–50%. Docetaxel and pemetrexed are two drugs commonly used, and their effects in single-phase cell culture are well known. From the pharmacological point of view, it appears rational to hypothesize that sequential therapy effects can show better outcomes compared with traditional single-phase experiments. Considering this, the present study aimed to establish a first-line second-line adenocarcinoma treatment model, using the combination of cisplatin with docetaxel or pemetrexed in vitro in different sequential therapy timings. To test this, the human lung cancer A549 cell line was used. The inhibitory effect was determined by adding docetaxel following treatment with cisplatin and pemetrexed (Pem-Doc group) and comparing this with a group in which pemetrexed was added subsequent to treatment with cisplatin and docetaxel (Doc-Pem group). Additionally, the differences in the gene and protein expression levels of excision repair cross-completion gene 1 (ERCC1), a gene that promotes drug resistance to cisplatin, were compared between the two groups. The present results showed that the inhibitory effect of cell proliferation in the Pem-Doc group was increased compared with that of Doc-Pem group, while the gene expression and protein levels of ERCC1 in the Pem-Doc group were decreased compared with those of Doc-Pem group. The Pem-Doc treatment plan is more effective in inhibiting cell proliferation and in lowering the expression of the ERCC1 gene. Therefore, Pem-Doc may be a more effective adenocarcinoma treatment.

show abstract

Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549

Cited by 7 publications

References 36 publications

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

Novel recombinant protein FlaA N/C increases tumor radiosensitivity via NF-κB signaling in murine breast cancer cells

Establishment of a first-line second-line treatment model for human pulmonary adenocarcinoma

Contact Info

Product

Resources

About